Design and evaluation of ‘Linkerless’ hydroxamic acids as selective HDAC8 inhibitors
Graphical abstract
Section snippets
Acknowledgments
We thank Chris Roessler for early work on this project. Figure 2, Figure 3, Figure 6 were generated with PyMol (Delano Scientific). This work was supported by the Research Corporation’s Cottrell College Science Award #CC5955 (S.M.U.) and The Gladstone Institutes (E.V.).
References and notes (22)
- et al.
Cell
(1999) - et al.
Curr. Biol.
(2004) - et al.
Cell
(1995) - et al.
Mol. Cell
(2003) - et al.
Curr. Opin. Struct. Biol.
(2005) - et al.
Adv. Cancer Res.
(2004) - et al.
J. Mol. Biol.
(2005) - et al.
Structure
(2004) - et al.
Am. J. Pathol.
(2004) - et al.
Science
(2001)
Gene Dev.
(1998)
Cited by (176)
Are inhibitors of histone deacetylase 8 (HDAC8) effective in hematological cancers especially acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL)?
2023, European Journal of Medicinal ChemistryTargeting cancers and metabolic disorders: The prospects of combining HDAC8 inhibitor and activator
2023, European Journal of Medicinal Chemistry ReportsTargeting epigenetic regulation for cancer therapy using small molecule inhibitors
2023, Advances in Cancer ResearchHistone Deacetylase Inhibitors and Psychiatric Disorders
2021, Epigenetics in Psychiatry
Copyright © 2007 Elsevier Ltd. All rights reserved.